Yes, Duchenne muscular dystrophy (DMD) is a genetic condition. It is caused by mutations in the DMD gene, located on the X chromosome, which provides instructions for making a protein called dystrophin. About 1 in 5,000 male births worldwide are affected, making it the most common severe form of muscular dystrophy.
But the genetics behind DMD are more nuanced than a simple “inherited from a parent” explanation. Roughly one-third of cases arise from brand-new, spontaneous mutations, meaning a child can develop DMD even with no family history. Understanding how the condition is passed on, who carries it, and how it’s detected can make a real difference for families navigating a diagnosis or planning for the future.
How DMD Is Inherited
DMD follows an X-linked recessive inheritance pattern. Males have one X chromosome (from their mother) and one Y chromosome (from their father). If the DMD gene on that single X chromosome carries a mutation, there is no backup copy to compensate, and the boy will have the condition.
Females have two X chromosomes. If one copy of the DMD gene is mutated, the second copy can usually produce enough dystrophin to prevent full-blown disease. This is why DMD overwhelmingly affects boys. A woman who carries one mutated copy is called a carrier. With each pregnancy, a carrier mother has a 50% chance of passing the mutated gene to any child. Sons who inherit it will have DMD; daughters who inherit it will typically be carriers themselves.
About two-thirds of mothers of boys with DMD are carriers. The remaining third of cases come from de novo mutations, meaning the genetic change happened spontaneously either in the egg cell or very early in the child’s development. Germline mosaicism, where a parent carries the mutation in some of their egg or sperm cells but not in their blood cells, accounts for roughly 19% of cases. This is why even mothers who test negative as carriers can still have more than one affected child.
What the Mutated Gene Does to Muscle
The DMD gene is one of the largest genes in the human body, spanning 79 sections (called exons). It encodes the dystrophin protein, which acts like an internal shock absorber for muscle cells. Dystrophin sits just beneath the surface of each muscle fiber, anchoring the cell’s internal scaffolding to its outer membrane and, through that membrane, to the surrounding tissue.
Every time a muscle contracts, the cell membrane experiences mechanical stress. Dystrophin and its associated protein complex absorb that stress and keep the membrane intact. Without dystrophin, the membrane becomes fragile. Repeated contractions tear tiny holes in it, allowing calcium and other substances to flood into the cell. Over time, muscle fibers die and are replaced by scar tissue and fat, which is why boys with DMD progressively lose strength.
Types of Mutations in the DMD Gene
Not all DMD mutations look the same at the genetic level, and knowing the specific type matters for treatment options. A large international database of over 7,000 DMD mutations found that about 80% are large-scale changes: 69% are deletions (where one or more exons are missing entirely) and 11% are duplications (where exons are repeated). The remaining 20% are small mutations, including point mutations where a single DNA letter is changed or a small insertion or deletion disrupts the gene’s reading frame.
Deletions tend to cluster in certain hotspot regions of the gene, while point mutations are scattered randomly across all 79 exons. The distinction between DMD and the milder Becker muscular dystrophy often comes down to whether the mutation completely destroys the reading frame (producing no functional dystrophin, causing DMD) or simply shortens it (producing a partially functional protein, causing Becker).
How DMD Is Diagnosed Genetically
When a boy shows early signs of muscle weakness, the first step is usually a blood test measuring creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. In healthy individuals, CK levels typically fall between 35 and 232 U/L. In boys with DMD, levels are dramatically elevated, often 10 to 100 times the normal range, with the highest readings occurring between ages 2 and 5. One study recorded levels up to 46.7 times the upper limit of normal. An extremely high CK level in a young boy is a strong signal that genetic testing should follow.
The standard first-line genetic test is called MLPA (multiplex ligation-dependent probe amplification), which screens all 79 exons of the DMD gene simultaneously for deletions and duplications. Since these large rearrangements account for roughly 80% of mutations, MLPA catches most cases in a single test. If MLPA comes back normal, gene sequencing is used to search for the smaller point mutations that make up the remaining 20%. Together, these two approaches identify the causative mutation in the vast majority of patients.
Can Girls Get DMD?
Full-blown DMD in girls is extremely rare, but being a carrier is not always symptom-free. Approximately 8% of female carriers are “manifesting carriers,” meaning they develop noticeable muscle weakness. Symptoms can appear anywhere from childhood to the late twenties and tend to be asymmetrical, affecting one side of the body more than the other. Among those who do develop weakness, about 41% have it primarily in the upper body, 23% mainly in the legs, and 36% in both.
Heart involvement is even more common. Research has found signs of cardiac problems in 55% of carriers under age 16 and in 90% of carriers over 16, particularly a form of heart enlargement called dilated cardiomyopathy. Abnormal heart tracings on an ECG show up in roughly 7 to 16% of female carriers. Because of this, medical guidelines recommend that all confirmed carriers receive regular cardiac monitoring throughout their lives, even if they never develop muscle weakness.
Carrier Testing and Family Planning
Once a mutation has been identified in a boy with DMD, his mother, sisters, and other female relatives on the maternal side can be tested to determine whether they carry the same mutation. This is straightforward when the mutation is a deletion or duplication detectable by MLPA. For point mutations, targeted sequencing of the known variant is used.
A negative carrier test in the mother does not completely eliminate risk for future pregnancies. Germline mosaicism, where the mutation exists in a fraction of the mother’s egg cells but not in her blood, cannot be detected by standard blood-based genetic testing. Genetic counseling typically estimates that even when a mother tests negative, there remains a small residual risk. For families considering future pregnancies, prenatal testing or preimplantation genetic testing during IVF can identify whether a specific embryo or fetus has inherited the mutation.
Gene-Based Treatment Approaches
Because DMD is caused by a single gene, it has been a major focus of gene-targeted therapies. Several exon-skipping treatments have been developed, each designed for patients with specific deletion patterns. These work by causing the cell’s machinery to skip over the disrupted portion of the gene during protein production, resulting in a shorter but partially functional dystrophin, essentially converting severe DMD into something closer to milder Becker muscular dystrophy.
A gene therapy called Elevidys took a different approach, delivering a miniaturized version of the dystrophin gene (producing a protein about one-third the size of full-length dystrophin) directly into muscle cells using a harmless virus as a delivery vehicle. It was administered as a single intravenous infusion. However, the FDA requested that its manufacturer suspend distribution following reports of serious adverse events, highlighting both the promise and the ongoing challenges of gene therapy for this condition. The type of mutation a patient carries directly determines which, if any, of these targeted treatments may be an option, which is one reason precise genetic diagnosis matters so much.